ArticleBMC psychiatry2026
Effect of age, sex, and BMI on serum olanzapine levels and their correlation with metabolic parameters and serum pro-inflammatory cytokine levels in schizophrenia patients.
Article in BMC psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Putative Neuroimmune Mechanisms and Candidate Biomarkers of rTMS Efficacy in Improving Negative Symptoms of Schizophrenia: Evidence Boundaries and Translational Pathways.Neuropsychiatric disease and treatment · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveOlanzapine is an atypical antipsychotic drug which is effective in the treatment of schizophrenia (SCZ). Olanzapine exhibits significant pharmacokinetic variability and is associated with a higher propensity for metabolic abnormalities. Recent evidence indicates that the immune system may play a role in antipsychotic-induced metabolic abnormalities through antipsychotic-induced modifications of cytokine levels. This study examined the effect of age, sex, and BMI on serum olanzapine levels and their correlation with metabolic parameters and serum pro-inflammatory cytokine levels in SCZ patients.
methodsA cohort of 104 SCZ patients receiving olanzapine treatment was recruited retrospectively for the investigation. Based on gender, age, and body mass index (BMI), the patients were divided into two groups each. Following a 4-week olanzapine treatment, the serum olanzapine concentrations and concentration/dose (C/D) ratios were compared between the two groups. The associations between the age, sex, and BMI with the serum olanzapine concentrations and C/D ratios were examined. Additionally, the relationship between the metabolic parameters and serum pro-inflammatory cytokine levels with the serum olanzapine concentrations and C/D ratios was analyzed.
resultsFemale patients exhibited higher serum olanzapine concentrations (t = -3.523, P = 0.001) and C/D ratios (t = -2.816, P = 0.006) compared to male patients. Moreover, the gender exhibited a positive correlation with the serum olanzapine concentrations (r = 0.329, P = 0.001) and C/D ratios (r = 0.269, P = 0.006). The BMI exhibited a negative correlation with the serum olanzapine concentrations (r = -0.205, P = 0.037), but not the C/D ratios (r = -0.185, P = 0.060). Furthermore, no significant relationship was observed between the metabolic parameters with the serum olanzapine concentrations (P > 0.05). Additionally, the serum olanzapine concentrations were negatively correlated with the serum IL-1β (r = -0.530, P < 0.001), IL-6 (r = -0.446, P < 0.001), and TNF-α (r = -0.464, P < 0.001).
conclusionThe patients' gender and BMI might affect the serum olanzapine concentrations. The serum olanzapine concentrations were negatively correlated with the serum IL-1β, IL-6, and TNF-α levels, but not with metabolic parameters during a short-term use of olanzapine in Chinese patients with SCZ.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.